NeuroPace, Inc. (NPCE)Healthcare | Medical Devices | Mountain View, United States | NasdaqGM
14.41 USD
+0.28
(1.982%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 14.41 |
Hot Take ↕ | Aug. 22, 2026, 1:10 a.m. EDT
NeuroPace presents a classic value trap where a 'strong buy' analyst recommendation clashes violently with deteriorating business reality. The company is burning significant cash, posting negative operating margins, and trading at a premium to book value despite having no earnings and a negative forward P/E. While revenue growth remains positive, the multi-year price trajectory tells a different story: the stock has lost more than half its value over the last four years, reflecting the market's skepticism regarding the company's ability to sustain operations without capital infusion. The recent news of FDA requests for more evidence and the denial of label expansion attempts further erode confidence in the product pipeline. With a beta of nearly 2.0, the stock is highly volatile and currently trading below its 50-day moving average, confirming a lack of short-term momentum. The options market confirms this pessimism, with heavy put buying at the bottom of the range and almost no speculative call volume. This is not a turnaround candidate ready for immediate entry; it is a high-risk speculative bet requiring proof of commercial viability that has yet to materialize. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.094561 |
| AutoARIMA | 0.094562 |
| MSTL | 0.099472 |
| AutoTheta | 0.109772 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 11.83 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.392 |
| Excess Kurtosis | -0.81 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 588.496 |
| Revenue per Share | 3.185 |
| Market Cap | 494,612,768 |
| Forward P/E | -64.86 |
| Beta | 1.94 |
| Profit Margins | -17.86% |
| Website | https://www.neuropace.com |
As of Aug. 22, 2026, 1:10 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest is concentrated deep out-of-the-money at the $5 strike, suggesting a fear of a collapse to near-zero levels. Call activity is sparse and skewed toward out-of-the-money strikes ($20), indicating limited conviction in a near-term rally despite the high implied volatility.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.54595184 |
| Address1 | 455 North Bernardo Avenue |
| All Time High | 27.38 |
| All Time Low | 1.22 |
| Ask | 17.12 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 149,950 |
| Average Daily Volume3 Month | 190,780 |
| Average Volume | 190,780 |
| Average Volume10Days | 149,950 |
| Beta | 1.937 |
| Bid | 10.16 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 0.347 |
| City | Mountain View |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.41 |
| Current Ratio | 4.944 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 14.55 |
| Day Low | 13.9 |
| Debt To Equity | 588.496 |
| Display Name | NeuroPace |
| Earnings Call Timestamp End | 1,786,480,200 |
| Earnings Call Timestamp Start | 1,786,480,200 |
| Earnings Timestamp | 1,786,478,400 |
| Earnings Timestamp End | 1,793,736,000 |
| Earnings Timestamp Start | 1,793,736,000 |
| Ebitda | -11,877,000 |
| Ebitda Margins | -0.11101 |
| Enterprise To Ebitda | -43.18 |
| Enterprise To Revenue | 4.793 |
| Enterprise Value | 512,844,800 |
| Eps Current Year | -0.4454 |
| Eps Forward | -0.22218 |
| Eps Trailing Twelve Months | -0.48 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 15.2316 |
| Fifty Day Average Change | -0.82159996 |
| Fifty Day Average Change Percent | -0.05394049 |
| Fifty Two Week Change Percent | 54.595184 |
| Fifty Two Week High | 19.6 |
| Fifty Two Week High Change | -5.1900005 |
| Fifty Two Week High Change Percent | -0.26479593 |
| Fifty Two Week Low | 8.883 |
| Fifty Two Week Low Change | 5.5269995 |
| Fifty Two Week Low Change Percent | 0.6221996 |
| Fifty Two Week Range | 8.883 - 19.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,619,098,200,000 |
| Float Shares | 25,641,262 |
| Forward Eps | -0.22218 |
| Forward P E | -64.85732 |
| Free Cashflow | -2,629,250 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 220 |
| Fullday Change | 0.28 |
| Fullday Change Percent | 1.9816 |
| Fullday Price | 14.41 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.77382004 |
| Gross Profits | 82,793,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04009 |
| Held Percent Institutions | 0.93894994 |
| Implied Shares Outstanding | 34,324,274 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,021-04-22 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California. |
| Long Name | NeuroPace, Inc. |
| Market | us_market |
| Market Cap | 494,612,768 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_125322 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -16,173,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 485,345,234 |
| Number Of Analyst Opinions | 9 |
| Open | 14.09 |
| Operating Cashflow | -11,241,000 |
| Operating Margins | -0.22531 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 650 237 2700 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 14.41 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 14.13 |
| Price Eps Current Year | -32.35294 |
| Price Hint | 2 |
| Price To Book | 41.527378 |
| Price To Sales Trailing12 Months | 4.622852 |
| Profit Margins | -0.17864999 |
| Quick Ratio | 3.822 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.11111 |
| Region | US |
| Regular Market Change | 0.28 |
| Regular Market Change Percent | 1.9816 |
| Regular Market Day High | 14.55 |
| Regular Market Day Low | 13.9 |
| Regular Market Day Range | 13.9 - 14.55 |
| Regular Market Open | 14.09 |
| Regular Market Previous Close | 14.13 |
| Regular Market Price | 14.41 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 129,419 |
| Return On Assets | -0.0747 |
| Return On Equity | -1.03273 |
| Revenue Growth | 0.171 |
| Revenue Per Share | 3.185 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 34,324,274 |
| Shares Percent Shares Out | 0.024600001 |
| Shares Short | 845,369 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 874,337 |
| Short Name | Neuropace, Inc. |
| Short Percent Of Float | 0.028299998 |
| Short Ratio | 3.76 |
| Source Interval | 15 |
| State | CA |
| Symbol | NPCE |
| Target High Price | 22.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 20.22222 |
| Target Median Price | 20.0 |
| Total Cash | 51,699,000 |
| Total Cash Per Share | 1.506 |
| Total Debt | 69,931,000 |
| Total Revenue | 106,993,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.48 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 15.4306 |
| Two Hundred Day Average Change | -1.0206003 |
| Two Hundred Day Average Change Percent | -0.06614132 |
| Type Disp | Equity |
| Volume | 129,419 |
| Website | https://www.neuropace.com |
| Zip | 94,043 |